Reevaluating the Safety of AAV Vectors in Gene Therapy for Retinal diseases

Gene therapies using AAV (Adeno-Associated Viruses) as viral vectors seem not to be safe as previously thought. Perhaps it is time to focus on different strategies.
The research found out that inherent properties of the AAV vector platform can likely cause or aggravate the development of progressive chorioretinal atrophy. The concerns raised about the safety of AAV vectors in gene therapies, particularly regarding the potential for causing or aggravating progressive chorioretinal atrophy, are significant. This has implications for the broader use of AAV in gene therapy, beyond just the treatment of retinal degenerative diseases.
Given these concerns, it may indeed be prudent to explore alternative strategies for gene delivery and therapy. Here are a few potential alternatives:
1. Non-Viral Gene Delivery Systems
Non-viral methods of gene delivery include the use of nanoparticles, liposomes, and other physical or chemical methods to introduce genetic material into cells. These systems generally have a lower risk of eliciting an immune response and can be designed to minimize off-target effects.
2. Alternative Viral Vectors
Adenoviral vectors: Although they can provoke stronger immune responses, adenoviral vectors do not integrate into the host genome, reducing the risk of insertional mutagenesis.
Retroviral vectors: These are similar to lentiviral vectors but have different integration properties and can be used for certain applications where stable, long-term expression is needed.
3. CRISPR
CRISPR genome editing technology offers a different approach by directly modifying the genome at specific sites. While delivery of the CRISPR components still presents challenges, non-viral methods or transient viral vectors (such as adenoviral vectors that do not integrate) can be used to introduce these components into cells.
4. Exosome-Mediated Delivery
Exosomes are small vesicles naturally used by cells for communication. They can be engineered to carry genetic material and deliver it to specific cell types. This method leverages the body's own mechanisms for transport and reduces the risk of immune reactions.
5. RNA-Based Therapies
Instead of delivering DNA, RNA-based therapies can modulate gene expression or correct genetic defects. Lipid nanoparticles or other delivery systems can be used to transport RNA molecules into cells.
----------------------------------------------------------------------------------------------------------------------
For more information and online order of AC STIM:
www.restorevis...
For information about V20 Light, please check:
www.restorevis...
For more information and online order of StemActiv :
www.restorevis...
For more information about OCU-ION:
www.restorevis...
Contact us for any question about restore vision:
[e-mail]

[@MallikarjunaRaoSanapally]

What about bionic eyes..?

[@sumankumarisah8097]

Ocu400 gene therapy when available trat rp